[Translated article] Utilization of emicizumab in the treatment of a case of acquired haemophilia A

Ocaña Gómez, María Ángeles; Esquivel Negrín, Jorge; Ríos De Paz, Mario; De Dios García, María Dolores

doi:10.1016/j.farma.2023.10.002

Farmacia Hospitalaria

2024

DOI: 10.1016/j.farma.2023.10.002

|View full text |Cite

[Translated article] Utilization of emicizumab in the treatment of a case of acquired haemophilia A

María Ángeles Ocaña Gómez,

Jorge Esquivel Negrín,

Mario Ríos De Paz

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside

Evangelidis,

Kotsiou,

Evangelidis

et al. 2024

CIMB

View full text Add to dashboard Cite

Acquired hemophilia A (AHA) is a bleeding disorder characterized by the immunological inhibition of factor VIII (FVIII) of the hemostatic pathway leading to hemorrhagic events. Different domains of FVIII are the target of autoantibodies (mainly immunoglobulin (Ig) G) leading to the deficiency of FVIII. Several factors have been associated with the activation of the auto-immunity towards FVIII. Emerging evidence implicates CD4+ T cell activation in mediating this autoimmune response, with their involvement like that observed in congenital hemophilia A. Several genes such as HLA II DRB*16, DQB1*0502, and CTLA-4 + 49 are responsible for the pathogenesis of AHA. Epigenetic modifications and mainly long-coding RNAS (lncRNAs) are potentially contributing to the pathogenesis of AHA. The treatment approach of AHA includes the management of acute bleeding events and the administration of immunosuppressive medications. This review aimed to summarize the published data on the genetics and epigenetics of AHA. The severity and the mortality of this disease are creating an emerging need for further research in the field of the genetics and epigenetics of acquired hemorrhagic disorder.

show abstract

Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside

Evangelidis,

Kotsiou,

Evangelidis

et al. 2024

CIMB

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

[Translated article] Utilization of emicizumab in the treatment of a case of acquired haemophilia A

Cited by 1 publication

References 9 publications

Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside

Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside

Contact Info

Product

Resources

About